TM editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.
A little-known, visionary biotech company is gearing up to release a potentially ground-breaking medical device that could help prevent strokes. It could help save six million lives a year—or a life every 4 minutes.
The unique new technology is the Carotid Stenotic Scan (CSS), by CVR Medical, and its futuristic system is designed to sense the leading indicator of strokes in only 2 minutes, and at a cost that will make it affordable and accessible to everyone.
CVR Medical (TSX:CVM.V ; OTC:CRRVF) is ready to burst out of the gate directly into a massive market. Here’s why:
This is unprecedented: Pre-stroke intervention has never before been affordable and accessible
It’s not invasive and preliminary tests demonstrate that in most cases it takes only 2 minutes
The patented technology is positioned to own this huge market segment
A CSS unit costs roughly $49,000, while current technology costs up to $2.5 million, making it economically out of reach
Over 230,000 medical facilities in the U.S. alone could potentially want the device, and globally the demand could be huge
The visionary team has invested $23 million in development and is expecting preliminary clinical results any day now
For the First Time in History: An Affordable Solution to a Multi-Billion-Dollar Problem
Stroke statistics are shocking: Globally, every year 15 million people suffer a stroke. In the U.S. alone, nearly 800,000 people suffer from a stroke annually.
Currently, one out of every 20 deaths in America is caused by stroke, making this one of the most pressing medical problems of our time.
Until now, there has been no cost-effective way to screen for the leading indicator of Ischemic strokes, which cost the U.S. government alone over 30 billion dollars a year in healthcare expenses.
